Alternatives thérapeutiques à la L-asparaginase native dans le traitement de la leucémie aiguë lymphoblastique de l'adulte

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Bulletin Du Cancer

• Publication date

  2010-09-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1684/BDC.2010.1168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute lymphoblastic leukemia

  2016cited by this paper
• Pharmacokinetics and Pharmacodynamics in Mice of a Pegylated Recombinant Erwinia Chrysanthemi-Derived L-Asparaginase.

  2009cited by this paper
• Chemotherapy of acute leukemia in adults

  2009cited by this paper
• Treatment of adults with BCR‐ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen

  2009cited by this paper
• Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

  2009cited by this paper
• Pegasparaginase: where do we stand?

  2009cited by this paper
• Targeting CK2 Overexpression as a Novel Therapeutic Tool in Chronic Lymphocytic Leukemia.

  2009cited by this paper
• Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

  2008cited by this paper
• Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?

  2008cited by this paper
• Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

  2008cited by this paper
• Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients.

  2008cited by this paper
• Iron Chelation by Deferoxamine Induces Autophagy

  2008cited by this paper
• Short-course imatinib (IM) added to chemotherapy improves early but not long-term outcome in adult Ph/BCR-ABL+ acute lymphoblastic leukemia (ALL) : 5-year follow-up results of study NILG-09

  2008cited by this paper
• Acute lymphoblastic leukemia in adolescents and young adults in Finland

  2008cited by this paper
• What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.

  2008cited by this paper
• GRASPALL 2005.01 Clinical Study: L-Asparaginase Loaded into Red Blood Cells Is Effective at Depleting Serum Asparagine in Children and Adults with Relapsed Acute Lymphoblastic Leukaemia (ALL)

  2008cited by this paper
• PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

  2008cited by this paper
• Structural Aspects of Hepcidin-Ferroportin Binding

  2008cited by this paper
• Toxicities in Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Regimens Using Pegasparaginase.

  2008cited by this paper
• Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

  2007cited by this paper
• Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.

  2007cited by this paper
• Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients

  2007cited by this paper
• Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials

  2007cited by this paper
• Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

  2007cited by this paper
• L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.

  2006cited by this paper
• A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.

  2006cited by this paper
• Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden

  2006cited by this paper
• Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

  2005cited by this paper
• Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.

  2005cited by this paper
• Asparagine Concentration in Plasma After 2 500 IU/m² PEG-Asparaginase i.v. in Children With Acute Lymphoblastic Leukemia

  2005cited by this paper
• Pancréatites aiguës sévères à l'asparaginase chez l'enfant: étude rétrospective multicentrique.

  2005cited by this paper
• Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations

  2005cited by this paper
• Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961

  2004cited by this paper
• Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands

  2004cited by this paper
• MONITORING THE ASPARAGINASE ACTIVITY AND ASPARAGINE LEVELS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH DIFFERENT ASPARAGINASE PREPARATIONS

  2004cited by this paper
• Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia

  2004cited by this paper
• Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin

  2004cited by this paper
• High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?

  2004cited by this paper
• [Acute lymphoblastic leukemia in elderly: prognosis and treatment].

  2004cited by this paper
• Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

  2004cited by this paper
• The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?

  2004cited by this paper
• Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.

  2003cited by this paper
• Pegylated asparaginase in combination with high‐dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study

  2003cited by this paper
• Stratégies thérapeutiques actuelles dans les leucémies aiguës lymphoblastiques de l‘adulte

  2003cited by this paper
• Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.

  2002cited by this paper
• A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

  2002cited by this paper
• Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL).

  2002cited by this paper
• Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

  2000cited by this paper
• Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia

  2000cited by this paper
• Combination therapy with methotrexate, vincristine, polyethylene‐glycol conjugated‐asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia

  1999cited by this paper
• Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.

  1999cited by this paper
• Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.

  1999cited by this paper
• Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

  1999cited by this paper
• The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.

  1999cited by this paper
• Use of L-asparaginase in childhood ALL.

  1998cited by this paper
• Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA

  1997cited by this paper
• Improved pharmacodynamics of l-asparaginase-loaded in human red blood cells

  1996cited by this paper
• Improved outcome in adult B-cell acute lymphoblastic leukemia.

  1996cited by this paper
• Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

  1996cited by this paper
• A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

  1995cited by this paper
• The biology and treatment of acute lymphoblastic leukemia in adults.

  1995cited by this paper
• An open‐label, multicenter study of polyethylene glycol‐L‐asparaginase for the treatment of acute lymphoblastic leukemia

  1995cited by this paper
• Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia.

  1993cited by this paper
• Comparative pharmacokinetic studies of three asparaginase preparations.

  1993cited by this paper
• Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.

  1993cited by this paper
• Erythrocytes as Carriers for L‐Asparaginase. Methodological and Mouse In‐vivo Studies

  1990cited by this paper
• A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.

  1988cited by this paper
• Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults

  1988cited by this paper
• Determination of Parameters for Enzyme Therapy Using L‐Asparaginase Entrapped in Canine Erythrocytes

  1988cited by this paper
• L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.

  1987cited by this paper
• Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase.

  1986cited by this paper
• [Permeability of human erythrocytes to asparagine].

  1985cited by this paper
• Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes.

  1985cited by this paper
• Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.

  1983cited by this paper
• L-Asparaginase: discovery and development as a tumor-inhibitory agent.

  1981cited by this paper
• Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.

  1980cited by this paper
• Factors related to length of complete remission in adult acute leukemia

  1980cited by this paper
• Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group.

  1979cited by this paper
• Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood

  1979cited by this paper
• Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia

  1978cited by this paper
• Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia.

  1977cited by this paper
• Hypersensitive reactions and antibody formation during L‐asparaginase treatment of children and adults with acute leukemia

  1976cited by this paper
• DISCUSSION PAPER: L‐ASPARAGINASE INDUCED ALTERATION OF AMETHOPTERIN (METHOTREXATE) ACTIVITY IN MOUSE LEUKEMIA L5178Y

  1971cited by this paper
• Toxicity of E. coli L‐asparaginase in man

  1970cited by this paper
• Evaluation of L-asparagine metabolism in animals and man.

  1970cited by this paper
• Escherichia coli L-asparaginase. Catalytic activity and subunit nature.

  1970cited by this paper
• Biochemical and pharmacological studies with asparaginase in man.

  1970cited by this paper
• l-asparaginase resistance in human leukemia--asparagine synthetase.

  1969cited by this paper
• TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI.

  1964cited by this paper
• Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects

  1961cited by this paper
• REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUM

  1953cited by this paper

• Bioprocess Optimization for Enhanced Production of L-asparaginase via Two Model-Based Experimental Designs by Alkaliphilic Streptomyces fradiae NEAE-82

  2020cites this paper
• Optimization of L-asparaginase production from novel Enterobacter sp., by submerged fermentation using response surface methodology

  2017cites this paper
• A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia

  2017cites this paper
• Recent developments in L-asparaginase discovery and its potential as anticancer agent.

  2016cites this paper
• Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

  2016cites this paper
• Optimization of Culture Conditions for Production of the Anti-Leukemic Glutaminase Free L-Asparaginase by Newly Isolated Streptomyces olivaceus NEAE-119 Using Response Surface Methodology

  2015cites this paper
• Microbial L-asparaginase as a Potential Therapeutic Agent for the Treatment of Acute Lymphoblastic Leukemia: The Pros and Cons

  2014cites this paper
• Le bilan de thrombophilie au diagnostic de leucémie aiguë lymphoblastique chez l’enfant : étude rétrospective au CHU de Bordeaux

  2014cites this paper
• Cell-based drug-delivery platforms.

  2012cites this paper
• [Novel conventional therapies in onco-hemathology].

  2011cites this paper